7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma

H.Akaza; S.Naito; T.Tsukamoto; M.Murai; K.Fukino

首页> 外文期刊>European Journal of Cancer Supplements >7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma

【24h】

7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma

机译：7147长期使用索拉非尼的疗效和安全性：索拉非尼在日本不可切除/转移性肾细胞癌患者中进行的II期临床试验的最终报告

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共2页
作者
H.Akaza; S.Naito; T.Tsukamoto; M.Murai; K.Fukino;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma [J] . H.Akaza, S.Naito, T.Tsukamoto, European Journal of Cancer Supplements . 2009,第2期

机译：7147长期使用索拉非尼的疗效和安全性：索拉非尼在日本不可切除/转移性肾细胞癌患者中进行的II期临床试验的最终报告
2. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. [J] . Naito S, Tsukamoto T, Murai M, BJU international . 2011,第11期

机译：细胞因子治疗后长期使用索拉非尼的总生存期和良好的耐受性：索拉非尼在日本转移性肾细胞癌患者中进行的II期临床试验的最终结果。
3. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: Subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial [J] . UedaT., UemuraH., TomitaY., Japanese journal of clinical oncology. . 2013,第6期

机译：阿昔替尼与索拉非尼在转移性肾细胞癌中的疗效和安全性：来自全球随机3期AXIS试验的日本患者的亚组分析
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial [O] . Takeshi Ueda, Hirotsugu Uemura, Yoshihiko Tomita, -1

机译：阿西替尼与索拉非尼在转移性肾细胞癌中的疗效和安全性：从全球随机3期AXIS试验中日本患者的亚组分析
7. Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma [O] . Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, 2011

机译：错误至：I阶段I的索拉非尼与日本患者的干扰素-α结合不可切除或转移性肾细胞癌

7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma

著录项

相似文献

相关主题

期刊订阅